Congressional Affairs

This webpage is a comprehensive, easy-to-navigate platform to enhance your understanding of DEA operations and to facilitate an ongoing collaboration with members of Congress and their staffs.

DEA’s OD Justice Devotes Critical Resources to Fatal Drug Poisoning and Overdose Death Investigations Across the United States

WASHINGTON – Operation OD Justice is a DEA initiative born out of a critical need to investigate drug poising and overdose deaths across the U.S. The initiative, launched in 2021 by DEA’s Los Angeles and San Diego Field Divisions, offers training, resources, and poisoning response coordinators to assist State and Local law enforcement as they investigate drug poisonings and overdose deaths.

Notice of Proposed Rulemaking (NPRM): Proposed Rescheduling of Marijuana

Schedules of Controlled Substances: Rescheduling of Marijuana - (NEW)
PROPOSED RULE: Schedules of Controlled Substances: Rescheduling of Marijuana
Notice of Proposed Rulemaking: Proposed Rescheduling of Marijuana
Basis for the Recommendation to Reschedule Marijuana into Schedule III of the Controlled Substances Act
Denial of Petition to Initiate Proceeding to Reschedule Marijuana Docket No. DEA-427
Denial of Petition to Initiate Proceeding to Reschedule Marijuana Docket No. DEA-426
Questions to OLC Related to the Potential Rescheduling of Marijuana

* 2 mg of fentanyl equates to a potentially deadly dose

DEA Fentanyl Seizures in 2024

In 2023, DEA seized more than 80 million fentanyl-laced fake pills and nearly 12,000 pounds of fentanyl powder. The 2023 seizures are equivalent to more than 390 million lethal doses of fentanyl.

The 2024 fentanyl seizures represent over 367 million deadly doses. *

Millions of Fentanyl Pills Seized

+ 55500000

Pounds of Fentanyl Powder Seized

+ lbs. 7888

* 2 mg of fentanyl equates to a potentially deadly dose

Intelligence Products

Fentanyl Supply Chain

Pill Press Resources

One Pill Can Kill

Press Releases

Recovery Resources

Drug Shortages/Stimulants

DEA and FDA Issue Joint Letter to the Public on Actions to Address Shortages in Prescription Stimulants

Update on the Prescription Stimulant Shortage (dea.gov)

Diversion Control Division | Stimulants (usdoj.gov)

Diversion Control Division | Quotas - 2023 Aggregate Production Quota for Methylphenidate (usdoj.gov)

DEA_Letter_to_Manufacturers.pdf (usdoj.gov)

Statements for the Record

February 1, 2023 - Statement of Associate Administrator Jon DeLena - Lives Worth Living: Addressing the Fentanyl Crisis, Protecting Critical Lifelines, and Combatting Discrimination Against Those with Disabilities

February 15, 2023 - Statement of Administrator Anne Milgram - Countering Illicit Fentanyl Trafficking

April 27, 2023 - Statement of Administrator Anne Milgram - Fiscal Year 2024 Request for the Drug Enforcement Administration

May 10, 2023 - Statement of Administrator Anne Milgram - A Review of the President’s Fiscal Year 2024 Funding Requests for the Federal Bureau of Investigation and for the U.S. Drug Enforcement Administration

June 21, 2023 - Statement of Matthew J. Strait Deputy Assistant Administrator Diversion Control Division - Responding to America's Overdose Crisis: An Examination of Legislation to Build Upon the SUPPORT Act

July 12, 2023 - Statement of Kemp L. Chester Senior Advisor, Office of National Drug Control Policy Committee on Homeland Security - Leading the Strategic Response to Disrupt the Flow of Illicit Fentanyl Across Our Borders

July 27, 2023 - Statement of Administrator Anne Milgram - Drug Enforcement Administration Oversight

October 24, 2023 - Statement of William F. Kimbell Chief of Operations Drug Enforcement Administration - Hearing Entitled, “TBD”

March 20, 2024 - Testimony of James Dunlap Deputy Under Secretary for Analysis Office of Intelligence and Analysis U.S. Department of Homeland Security - Examining the Current Status of Iran’s Axis of Resistance and the Implications for Homeland Security and U.S. Interests

April 30, 2024 - Statement of William F. Kimbell Chief of Operations Drug Enforcement Administration - Hearing Entitled, “TBD”

May 7, 2024 - Statement of Administrator Anne Milgram - Fiscal Year 2025 Request for the Drug Enforcement Administration

Publications

National Drug Threat Assessment 2024
The Growing Threat of Xylazine and its Mixture with Illicit Drugs (dea.gov)

Performance Budget

DEA FY 2025 Narrative

2024 | 2023 | 2022 | 2021

Contact Us

CongressionalAffairs@dea.gov